Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · people with serious mental illness
1 finding from 1 review
Social functioning · people with serious mental illness
1 finding from 1 review
QoL · people with serious mental illness
1 finding from 1 review
Compliance with medication · people with severe mental disorders
1 finding from 1 review
Cannabis use · patients with SCHIZOPHRENIA AND CANNABIS USE
1 finding from 1 review
**Mental state: Obsessive–Compulsive Drug Use Scale (OCDUS) (short‐term, higher=bad) ‐ short term Scale from: 0 to 44. · patients with schizophrenia
1 finding from 1 review
Cannabis use · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Mental state: PANSS total (high = bad) ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Mental state · patients with SCHIZOPHRENIA AND CANNABIS USE
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · patients with schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Mental state and behaviour DASS21. Scale from: 0 to 84 (high = poor) · patients with schizophrenia
It is very uncertain whether horticultural therapy plus standard care changes mental state and behaviour DASS21. Scale from: 0 to 84 (high = poor) compared with standard care alone (very low certainty).
1 finding from 1 review
Family outcome ‐ understanding schizophrenia, average endpoint score Patient Rejection Scale (PRS ‐ high score = greater acceptance). Scale from: 24 to 168. · patients with schizophrenia
1 finding from 1 review
Quality of life (change from baseline) in the medium term · patients with schizophrenia or related psychoses
1 finding from 1 review
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
1 finding from 1 review